Pathology News

The state of Connecticut Department of Public Health recently extended its agreement with Yale Pathology Labs to provide COVID testing on the New Haven Green and perform Whole Genome Sequencing testing on positive COVID samples to help inform lineage and variants in our region.

Andrea Barbieri, MD, Assistant Professor of Pathology, assumed the position of Director of the Pathology Residency Training Program on August 1.

Adebowale Adeniran, MD, Professor of Pathology, has been appointed as new Director of the Cytopathology Fellowship Program in the Department of Pathology at Yale School of Medicine effective August 1.

Despite a higher prevalence of triple-negative breast cancer (TNBC) among Black women compared to White women, Black women are underrepresented in TNBC clinical trials, particularly those involving novel immunotherapies. In a study published today in Clinical Cancer Research, researchers at Yale Cancer Center used data from a previous study showing that the combination of durvalumab and neoadjuvant chemotherapy was well tolerated and resulted in high pathologic complete response (pCR) rate in women with non-metastatic TNBC before surgery to recruit another group of racially diverse patients to see if the results were the same. Durvalumab is an immunotherapeutic that targets the PD-1/PD-L1 immune checkpoint pathway.

In a new study published in Science, Yale scientists describe an alternative drug to temozolomide that may overcome brain cancer's resistance to chemotherapy.

Yale researchers have developed a new class of molecules that target some of the deadliest brain cancers while sparing healthy tissue. The discovery combines innovative synthetic chemistry and cutting-edge mechanistic studies in molecular biology, and offers a potentially powerful new approach to treating drug-resistant glioma tumors.

An objective assessment of automated electronic tumor infiltrating lymphocytes percentage (eTILs%) scores is a strong prognostic marker in patients with early-stage melanoma. The study also identifies distinct TIL subpopulations that carry the prognostic values.

Epigenetic clocks are powerful biomarkers based on DNA methylation that were developed to track aging in population studies, clinical trials, and personal health applications. Intended to measure biological age, they strongly predict age-related morbidity and mortality along with other aspects of health. Now, scientists from Yale School of Medicine, in collaboration with international research colleagues, have developed a new approach to make them substantially more reliable.

Silvia Vilarinho, MD, PhD, assistant professor of medicine (digestive diseases) and of pathology; and associate director, Yale MD/PhD Program, has been appointed associate director of the Yale Internal Medicine Physician Scientist Training Program (PSTP).